EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

PSMA-targeted radioligand therapy with [177Lu]Lu-PSMA-I&T in metastatic castration-resistant prostate cancer: a prospective, multicentre, Swiss registry study

Alin Chirindel, Niklaus Schaefer, Maria del Sol Pérez Lago, Flavio Forrer, Ali Afshar-Oromieh, Stephan Beintner-Skawran, Andreas Bauman, Michael Coslovsky, Valentin Klotzbuecher, Marine Tissier, Andrea Zander, Ole Maas und 8 weitere

The Lancet Medical Imaging & Theranostics · 2026

DOI: 10.1016/j.lanmit.2026.100010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Lancet Medical Imaging & Theranostics, 2026. Verfasst von Alin Chirindel und 19 weiteren Autor:innen. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University Hospital Basel.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy is the leading theranostic strategy for metastatic castration-resistant prostate cancer (mCRPC). Randomised trials have shown survival benefit with [ 177 Lu]Lu-PSMA-617, but prospective multicentre real-world data for the widely used alternative ligand [ 177 Lu]Lu-PSMA-I&T remain scarce. In this study, we evaluated the safety and clinical activity of [ 177 Lu]Lu-PSMA-I&T in routine practice.

Methods

This prospective, multicentre, Swiss registry enrolled consecutive men older than 18 years with histologically confirmed prostate adenocarcinoma undergoing intravenous [ 177 Lu]Lu-PSMA-I&T therapy (7 GBq every 6 weeks for up to six cycles). Eligible patients had Eastern Cooperative Oncology Group performance status of 2 or less and PSMA-positive mCRPC with progressive disease after androgen receptor pathway inhibitor therapy or chemotherapy, or both, unless deemed unfit. The primary outcome was safety, assessed by treatment-emergent adverse events graded according to Common Terminology Criteria for Adverse Events (version 5.0). Assessments were performed at predefined timepoints before each treatment cycle and during the post-therapy follow-up. Secondary outcomes included the best prostate-specific antigen (PSA) response and PSA decline of 50% or more (PSA50) response according to the Prostate Cancer Working Group 3 criteria. All patients who underwent at least one treatment cycle were included in the final analysis of the observational registry. This study is registered at ClinicalTrials.gov, NCT06830408.

Findings

Between May 25, 2020, and June 4, 2024, 333 patients with mCRPC received [ 177 Lu]Lu-PSMA-I&T therapy and were included in the analysis. The median follow-up was 12·0 months (IQR 6·5–20·0). Grade 3 treatment-emergent haematological toxicities included anaemia in 26 (8·8%; 95% CI 5·8–12·6) of 295, thrombocytopenia in nine (3·1%; 1·4–5·7) of 295, leukopenia in five (1·7%; 0·6–3·9) of 295, lymphopenia in 54 (21·1%; 16·3–26·6) of 256, and neutropenia in one (0·4%; 0·0–2·2) of 256. No grade 3 or worse renal toxicity or grade 4–5 treatment-emergent adverse events were observed. Best PSA response was achieved in 198 (64·3%; 95% CI 58·7–69·6) of 308 patients and PSA50 in 137 (44·5%; 38·8–50·2). Interpretation [ 177 Lu]Lu-PSMA-I&T showed clinically meaningful activity with a favourable safety profile in heavily pretreated mCRPC. These findings provide prospective evidence supporting the safety and activity of PSMA-targeted radioligand therapy with [ 177 Lu]Lu-PSMA-I&T in routine clinical practice. Funding Swiss Hadron Foundation.

Förderung

  • University Hospital Basel

Zitieren

APA

Chirindel, A., Schaefer, N., Lago, M. D. S. P., Forrer, F., Afshar-Oromieh, A., Beintner-Skawran, S., Bauman, A., Coslovsky, M., Klotzbuecher, V., Tissier, M., Zander, A., Maas, O., Engel-Bicik, I., Lorch, A., Rentsch, C. A., Stenner, F., Templeton, A. J., Nitzsche, E., Wild, D., & Nicolas, G. P. (2026). PSMA-targeted radioligand therapy with [177Lu]Lu-PSMA-I&T in metastatic castration-resistant prostate cancer: a prospective, multicentre, Swiss registry study. The Lancet Medical Imaging & Theranostics. https://doi.org/10.1016/j.lanmit.2026.100010

Vancouver

Chirindel A, Schaefer N, Lago MDSP, Forrer F, Afshar-Oromieh A, Beintner-Skawran S, et al. PSMA-targeted radioligand therapy with [177Lu]Lu-PSMA-I&T in metastatic castration-resistant prostate cancer: a prospective, multicentre, Swiss registry study. The Lancet Medical Imaging & Theranostics. 2026. doi:10.1016/j.lanmit.2026.100010

BibTeX
@article{Chirindel2026,
  author = {Chirindel, Alin and Schaefer, Niklaus and Lago, Maria del Sol Pérez and Forrer, Flavio and Afshar-Oromieh, Ali and Beintner-Skawran, Stephan and Bauman, Andreas and Coslovsky, Michael and Klotzbuecher, Valentin and Tissier, Marine and Zander, Andrea and Maas, Ole and Engel-Bicik, Ivette and Lorch, Anja and Rentsch, Cyrill A and Stenner, Frank and Templeton, Arnoud J and Nitzsche, Egbert and Wild, Damian and Nicolas, Guillaume P},
  title = {PSMA-targeted radioligand therapy with [177Lu]Lu-PSMA-I&T in metastatic castration-resistant prostate cancer: a prospective, multicentre, Swiss registry study},
  journal = {The Lancet Medical Imaging & Theranostics},
  year = {2026},
  doi = {10.1016/j.lanmit.2026.100010}
}
Kostenlos starten →